![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Under their collaboration, Hovione and Zerion will now upscale and develop commercial formulations of the beta-lactoglobulin or BLG using the Dispersome® platform and make Lacprodan products available for distribution by partners globally.
Lead Product(s): Beta-lactoglobulin
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Recipient: Zerion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration August 23, 2022
Details:
Under the license agreement, JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization.
Lead Product(s): JX08
Therapeutic Area: Ophthalmology Product Name: JX08
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Ji Xing Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 09, 2022
Details:
This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: HY02
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Details:
The partnership aims to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product and a chemically modified cyclodextrin proven to improve the solubility and stability of drugs.
Lead Product(s): Modified Cyclodextrin
Therapeutic Area: Infections and Infectious Diseases Product Name: Captisol
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 23, 2020